| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/28/2004 | EP1383540A2 Methods and pharmaceutical compositions for healing wounds |
| 01/28/2004 | EP1383531A2 Use of lp82 to treat hematopoietic disorders |
| 01/28/2004 | EP1383530A2 Laminin 5, 13 and 14 and uses thereof |
| 01/28/2004 | EP1383527A1 Methods and compositions for treating oral and esophageal lesions |
| 01/28/2004 | EP1383522A2 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of inflammatory skin conditions |
| 01/28/2004 | EP1383521A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/28/2004 | EP1383520A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/28/2004 | EP1383515A1 Activation of natural killer cells by adenosine a3 receptor agonists |
| 01/28/2004 | EP1383511A2 Calcilytic compounds |
| 01/28/2004 | EP1383508A1 Methods of treating acne |
| 01/28/2004 | EP1383506A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7 |
| 01/28/2004 | EP1383504A1 Sustained release drug delivery system containing codrugs |
| 01/28/2004 | EP1383502A2 Compounds and methods for the treatment of urogenital disorders |
| 01/28/2004 | EP1383501A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/28/2004 | EP1383498A1 Crf receptor antagonists |
| 01/28/2004 | EP1383497A2 Carbonic anhydrase activators for enhancing learning and memory |
| 01/28/2004 | EP1383496A2 Treatment of fibromyalgia and related fatigue syndromes using pindolol |
| 01/28/2004 | EP1383495A1 Duloxetine for treatment of hot flashes |
| 01/28/2004 | EP1383494A2 Compositions and methods for the prevention and treatment of human prostate cancer |
| 01/28/2004 | EP1383493A1 Inhibition of pigmentation by inhibition of fatty acid synthase |
| 01/28/2004 | EP1383491A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 01/28/2004 | EP1383490A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/28/2004 | EP1383489A1 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 01/28/2004 | EP1383486A2 Compositions containing cgmp pde inhibitors and local anestetic agents for nasal application |
| 01/28/2004 | EP1383483A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 01/28/2004 | EP1383481A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 01/28/2004 | EP1383480A2 Lipid-comprising drug delivery complexes and methods for their production |
| 01/28/2004 | EP1383474A2 Methods and compositions that affect melanogenesis (pfi-016cip/pct) |
| 01/28/2004 | EP1383465A2 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| 01/28/2004 | EP1383463A2 Pharmaceutically active compounds and methods of use |
| 01/28/2004 | EP1383460A2 Crf 2? ligands in combination therapy |
| 01/28/2004 | EP1383447A1 Stent-based delivery of statins to prevent restenosis |
| 01/28/2004 | EP1383379A1 Restoration of cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 01/28/2004 | EP1299378A4 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/28/2004 | EP1268479B1 Phenyl-substituted indolizine derivatives and their use as histamine h3 ligands |
| 01/28/2004 | EP1183237B1 Novel antioxidants, preparation methods and uses |
| 01/28/2004 | EP1061944B1 Therapeutic chemokine receptor antagonists |
| 01/28/2004 | EP0966455B1 Oxiran carboxylic acids for the treatment of diabetes |
| 01/28/2004 | EP0906100B1 Use of 5-ht 1a? receptor antagonists for the treatment of urinary incontinence |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471538A Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 01/28/2004 | CN1471536A Chemokine receptor antagonsis and method of use thereof |
| 01/28/2004 | CN1471535A Tricyclic derivatives of indole with antiangiogenic activity |
| 01/28/2004 | CN1471534A 桥(连)哌嗪衍生物 Bridge (even) piperazine derivatives |
| 01/28/2004 | CN1471528A Pyrrolidine derivatives and their use as chymase inhibitor |
| 01/28/2004 | CN1471526A Dioxolane analogs for improved inter-cellular delivery |
| 01/28/2004 | CN1471524A Novel farnesyl protein transferase inhibitors as antitumor |
| 01/28/2004 | CN1471523A Imidazole derivatives as Raf kinase inhibitors |
| 01/28/2004 | CN1471517A OXAZOLYL-arylpropionic acid derivatives and their sue as PPAR agonists |
| 01/28/2004 | CN1471512A Gem-substituted ± ¢ ²3 integrin antagonists |
| 01/28/2004 | CN1471404A Antiparkinsonism drugs |
| 01/28/2004 | CN1471402A Compositions and methods for diagnosis and treatment of cardiovascualr disorders |
| 01/28/2004 | CN1471400A Combination therapy for the treatment of estrogen-sensitive disease |
| 01/28/2004 | CN1471397A Method for treatment of migraine |
| 01/28/2004 | CN1471395A Apomorphine derivatives and methods for their use |
| 01/28/2004 | CN1471394A Tripeptidyl peptidase inhibitors |
| 01/28/2004 | CN1471393A Method for the treatment of neurological and neuropsychological disorders |
| 01/28/2004 | CN1471392A Method for the treatment of neurological and neuropsychological disorders |
| 01/28/2004 | CN1471391A Composition and method for treatment of hypertriglyceridemia |
| 01/28/2004 | CN1471390A Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction |
| 01/28/2004 | CN1471387A Oral dosage self-emulsifying formulations of pyranone proteinase inhibitors |
| 01/28/2004 | CN1470290A Radioactive nano ferror nuclein medicine and its medical use |
| 01/28/2004 | CN1470251A Anti-anoxia microecological preparation and its production method |
| 01/28/2004 | CN1470249A Yak-blood deproteined extract and its extraction method and use thereof |
| 01/28/2004 | CN1470237A Use of chloroquine, hydroxychloroquine and 4-aminoquinazine derivatives in preparing medicine for antiretrovirus therapy |
| 01/28/2004 | CN1470235A Animal model of schizophrenia and its medicine sorting platform |
| 01/28/2004 | CN1136219C Pyrazolopyrimidinone derivatives for the treatment of impotence |
| 01/28/2004 | CN1136217C 4-aryloxindoles as inhibitor of JNK protein kinases |
| 01/28/2004 | CN1136213C New benzothiophene, benzofuran and indole compounds, preparation method there for and medicine composition containing them |
| 01/28/2004 | CN1136212C Thiophene nitrone compounds |
| 01/28/2004 | CN1136199C Process for preparing alpha-adrenergic receptor antagonist |
| 01/28/2004 | CN1136192C Aryl and hetaryl-sulfonamide derivatives, their preparation and use as endo thelin antagonists |
| 01/28/2004 | CN1136191C Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists |
| 01/28/2004 | CN1136189C Substituted heterocyclic compounds, preparing method thereof and pharmaceutical composition containig them |
| 01/28/2004 | CN1136187C 1-amino-alkylcyclohexane NMDA receptor antagonists |
| 01/28/2004 | CN1136004C Chinese medicine for relieving fatigue and resisting oxygen lack and its preparing process |
| 01/28/2004 | CN1135975C Vitamin E and esters therof for use in the topical treatment of mucosal pathologies |
| 01/28/2004 | CN1135933C Multifunctional nutritive liquid and its production method |
| 01/27/2004 | US6683200 N-substituted-n'-substituted urea derivative is used as a tumor necrosis factor-alpha production inhibitory agent and a therapeutical agent for autoimmune diseases |
| 01/27/2004 | US6683192 Substituted benzo(b)thien compounds useful for modulating proliferation or differentiation of a cell, agonizes hedgehog mediated signal trasnduction with an ed50 of 1mm or less |
| 01/27/2004 | US6683186 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| 01/27/2004 | US6683183 Bicyclic heterocycles that inhibit cyclin-dependent kinase or tyrosine kinase enzymes, or both, for treatment of proliferative disorders |
| 01/27/2004 | US6683181 Mixing polystyrene-tosyl chloride resin with c2-12alkynol; reacting with amine to make chemical intermediate; herpes virus treatment |
| 01/27/2004 | US6683103 Sulfonamides containing oxazole and substituted thiophene rings, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure |
| 01/27/2004 | US6683101 Such as 6-(3-(trans-4-phenylcyclohexylamino)propyl)-3h-benzoxazol-2-one; cerebral vascular disorders |
| 01/27/2004 | US6683097 Imidazole derivatives |
| 01/27/2004 | US6683095 CDK inhibitors having 3-hydroxychromen-4-one structure |
| 01/27/2004 | US6683093 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease |
| 01/27/2004 | US6683091 Heterocyclic sulfanamides; alzheimer's disease; preventing deposition of amyloid protein |
| 01/27/2004 | US6683090 N-(1-azabicyclo(2.2.2)oct-3-yl)propenamide derivatives; psychotic and intellectual impairment disorders |
| 01/27/2004 | US6683088 Sulfonamido ether substituted imidazoquinolines |
| 01/27/2004 | US6683081 Triazolotriazinones and the use thereof |
| 01/27/2004 | US6683078 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/27/2004 | US6683077 2-Amino-benzoxazinones for the treatment of viral infections |
| 01/27/2004 | US6683076 Methods for therapeutic use of glucosylceramide synthesis inhibitors and composition thereof |
| 01/27/2004 | US6683074 Cyclic amine derivatives-CCR-3 receptor antagonists |
| 01/27/2004 | US6683060 Chelating zinc with 1-(3,4-dihydroxy-5-(2-hydroxyethyl)-tetrahydrofuran-2-yl)pyrimidine -2,4(1h,3h)-dione; ovarian cancer |
| 01/27/2004 | US6683051 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 01/27/2004 | US6682928 Cell is transformed to express on its surface a component which binds to an fc receptor of an effector cell used as a vehicle to increase an cell lysis and phagocytosis against an antigen associated with the cell |
| 01/27/2004 | US6682735 Anti-IgE antibodies |